Rebecca Krochmal, MD
Pulmonary Disease · Washington, DCNPI 1700011632
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 97.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $4,921 and has fallen 88.1% since, to $584 in 2025.
Across 72 payments — averaging $121.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Coaptech, Inc.$148
- Johnson & Johnson$38
- Pulmonx Corporation$31
What the payments were for
- Travel & lodging$2,72431%
- Food & beverage$3,03935%
- Education$3,00034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 69 | $8,546 |
| Coaptech, Inc. | 1 | $148 |
| Johnson & Johnson | 1 | $38 |
| Pulmonx Corporation | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,286
- PUMA-G System$148
How this compares
$8,763 in reported general payments places this provider in the 85th percentile of 56 pulmonary disease providers in District of Columbia.
See all pulmonary disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $24,368 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,526 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,778 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,452 |
| EliquisApixaban | 11 | $6,176 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,518 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $2,673 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,029 |
| Prednisone | 15 | $117 |
| Azithromycin | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Washington
- Andrew ShorrWashington$349K
- Eric AndersonWashington$215K
- Anne OdonnellWashington$61K
- Andrew LernerWashington$19K
- Guillermo GutierrezWashington$14K
- Khalil DiabWashington$10K
- Lorenzo LeysWashington$9K
- Steven LernerWashington$6K
- Karen FaganWashington$6K
- Leslie KingslowWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.